Gelonghui November 29丨FuRui Medical Technology (01696.HK) announced that the registration application for Profhilo, an injectable filler product exclusively represented by the company in mainland China, has been accepted by the China National Drug Administration (China Drug Administration). This product is a physiological buffer solution of high molecular weight hyaluronic acid (H-HA) and low molecular weight hyaluronic acid (L-HA). It uses NAHYCO's patented blending technology to bring a better anti-aging experience to beauty seekers and patients.
The product is distributed exclusively by the company and is already sold in the markets of Israel, India and Hong Kong, China. If this registration application is approved by the State Drug Administration, it will enrich the company's injectable filler product portfolio in the mainland China market and promote the company's product development and market penetration in the medical and aesthetic field.